Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.1182/blood.v128.22.1141.1141
Abstract: This is a phase 2 dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma. The results of 4 dose levels are… read more here.
Keywords: dexamethasone induction; induction consolidation; transplant eligible; consolidation ... See more keywords